Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 February 2026Expected publication date: TBC